Custom service
Peptide-small-molecule Conjugation
Link peptides to small-molecule payloads through cleavable or non-cleavable linkers
Teams come to this service when they need to link peptides to small-molecule payloads through cleavable or non-cleavable linkers. We typically start from cleavable linker design (Val-Cit, disulfide), add non-cleavable amide and triazole linkages where the application demands it, and close the loop with payload solubilization strategy so the final conjugate with linker-attachment-site mapping behaves consistently across lots.
Design reviews are part of the schedule, not an extra. Sequence, spacer architecture and analytical strategy are signed off before the first synthesis run, which is why the 4–8 weeks timeline holds in practice.
Peptide–drug conjugate (PDC) discovery programmes
PROTAC-adjacent and targeted-degradation constructs
GMP payload conjugation for clinical dosing
Conjugates whose payload cannot tolerate aqueous coupling conditions
Every conjugation batch is documented from vial to vial: carrier lot, payload lot, reagent lots, reaction conditions and purification chromatograms. The release package contains the loading ratio measured by an orthogonal method (UV, ICP-MS or amino-acid analysis), identity by mass spectrometry where the conjugate permits it, and residual-free-payload data.
Service Highlights
- Cleavable linker design (Val-Cit, disulfide) as the default route, with non-cleavable amide and triazole linkages held as a proven fallback
- Payload solubilization strategy worked into the design where the application requires it
- Carrier and payload compatibility screened in a small feasibility batch before full material is committed
- Analytical confirmation of every intermediate before the final release
- Unreacted payload driven below the detection limit of the release assay before purification is closed
- Conjugate with linker-attachment-site mapping delivered with a complete conjugation or synthesis certificate
How the work runs
Scope & design
We review the payload, the carrier and the intended assay or study, and propose between cleavable linker design (Val-Cit, disulfide) and non-cleavable amide and triazole linkages as candidate routes.
Feasibility screen
A milligram-scale screen compares loading, residual payload and activity across the candidate conditions.
Production conjugation
The selected condition is executed at project scale with in-process sampling at fixed time points.
Purification
Size-exclusion, dialysis or magnetic separation removes free payload and by-products.
Characterization & release
Identity, loading ratio and functional activity are measured against the agreed specification.
Documentation & hand-off
Conjugate with linker-attachment-site mapping is packaged with the full batch record, released for shipment after QC sign-off.
Specifications & timeline
- Turnaround
- 4–8 weeks
- Typical scale
- 0.1–50 mg conjugate per batch
- Chemistry options
- cleavable linker design (Val-Cit, disulfide); non-cleavable amide and triazole linkages; payload solubilization strategy
- Deliverable
- Conjugate with linker-attachment-site mapping
- QC package
- HPLC/SEC trace, MALDI-TOF or ESI-MS, UV/Vis or ICP-MS loading ratio
- Shipping
- Blue ice or dry ice as the payload requires, with a cold-chain manifest
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.